Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
SG Americas Securities LLC increased its position in shares of The Chemours Company (NYSE:CC – Get Rating) by 24.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 56,213 shares of the specialty chemicals company’s stock after purchasing an additional 11,060 shares during the quarter. SG Americas Securities LLC’s holdings in Chemours were worth $1,386,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in CC. Asset Management One Co. Ltd. bought a new stake in Chemours in the second quarter valued at $25,000. CNB Bank bought a new stake in Chemours in the second quarter valued at $25,000. Trust Co. of Vermont bought a new stake in Chemours in the second quarter valued at $35,000. Ellevest Inc. lifted its stake in Chemours by 34,325.0% in the second quarter. Ellevest Inc. now owns 1,377 shares of the specialty chemicals company’s stock valued at $44,000 after buying an additional 1,373 shares during the last quarter. Finally, GPS Wealth Strategies Group LLC lifted its stake in Chemours by 82.9% in the second quarter. GPS Wealth Strategies Group LLC now owns 1,655 shares of the specialty chemicals company’s stock valued at $53,000 after buying an additional 750 shares during the last quarter. 71.89% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of research analysts have recently commented on CC shares. Royal Bank of Canada lowered Chemours from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $35.00 to $33.00 in a report on Tuesday, January 10th. The Goldman Sachs Group started coverage on Chemours in a report on Thursday, October 13th. They set a “neutral” rating and a $30.00 price target on the stock. Citigroup raised their price target on Chemours from $30.00 to $33.00 and gave the company a “neutral” rating in a report on Thursday, December 15th. Barclays raised their price target on Chemours from $30.00 to $34.00 in a report on Tuesday, November 1st. Finally, Credit Suisse Group started coverage on Chemours in a report on Tuesday, November 1st. They set an “underperform” rating and a $24.00 price target on the stock. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Chemours currently has a consensus rating of “Hold” and an average price target of $32.90.
Chemours Trading Up 0.9 %
Shares of CC opened at $33.58 on Tuesday. The business’s 50-day moving average price is $31.54 and its 200 day moving average price is $31.58. The stock has a market capitalization of $5.07 billion, a P/E ratio of 5.99, a P/E/G ratio of 0.67 and a beta of 1.84. The Chemours Company has a 1-year low of $22.56 and a 1-year high of $44.95. The company has a current ratio of 1.82, a quick ratio of 1.14 and a debt-to-equity ratio of 2.73.
Chemours (NYSE:CC – Get Rating) last issued its quarterly earnings results on Tuesday, October 25th. The specialty chemicals company reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.08. The firm had revenue of $1.80 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Chemours had a return on equity of 73.45% and a net margin of 12.91%. Chemours’s revenue was up 7.1% on a year-over-year basis. During the same quarter last year, the business posted $1.27 EPS. Analysts expect that The Chemours Company will post 4.74 earnings per share for the current year.
Chemours Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 15th. Shareholders of record on Tuesday, November 15th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Monday, November 14th. This represents a $1.00 dividend on an annualized basis and a yield of 2.98%. Chemours’s payout ratio is presently 17.83%.
Chemours Company Profile
(Get Rating)
The Chemours Co is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial.
Recommended Stories
- Get a free copy of the StockNews.com research report on Chemours (CC)
- $2,000 at Alphabet’s YouTube Purchase: You’d Be Up This Much.
- Michael Burry is Bearish on Stocks Again and Heres Why
- Don’t Miss These 2 Mid-Cap Techs That Broke Out Last Week
- Is Macau a Sinking Ship for Wynn Resorts?
- Why Warner Bros Discovery Is the S&P’s Hottest Stock
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chemours, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Chemours wasn’t on the list.
While Chemours currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Thinking about investing in Meta, Roblox, or Unity? Enter your email below to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2023. All rights reserved.
© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
